Drugs Made In America Acquisition (DMAAR) Non-Current Assets (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) reported Non-Current Assets of $239.9 million for Q4 2025, up 43852.39% on a YoY basis from N/an in Q4 2024, and up 0.97% quarter-over-quarter from $237.6 million in Q3 2025.

Drugs Made In America Acquisition (DMAAR) Non-Current Assets (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Non-Current Assets for 2 years, with the latest figure at $239.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 43852.39% year-over-year to $239.9 million; the trailing twelve-month figure through Dec 2025 stood at $239.9 million (up 43852.39% YoY), and the FY2025 full-year result was $239.9 million, up 43852.39% from the prior year.
  • Non-Current Assets for Q4 2025 stood at $239.9 million, up from $237.6 million in the prior quarter.
  • The five-year high for Non-Current Assets was $239.9 million in Q4 2025, with the low at $545833.0 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 472.84 Mn
2 Berto Acquisition 312.46 Mn 312.46 Mn - 311.36 Mn
3 Centurion Acquisition 311.65 Mn 311.65 Mn - 310.90 Mn
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - 309.18 Mn
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - 310.26 Mn
6 WEN Acquisition 309.15 Mn 309.15 Mn - 307.81 Mn
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - 272.15 Mn
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 259.89 Mn
9 BTC Development 262.16 Mn 262.16 Mn - 257.30 Mn
10 Drugs Made In America Acquisition - - - 239.91 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 239.91 Mn
Sep 30, 2025 237.60 Mn
Jun 30, 2025 235.16 Mn
Mar 31, 2025 232.74 Mn
Dec 31, 2024 545,833.00